Prasterone enanthate, also known as dehydroepiandrosterone enanthate (DHEA-E) and sold in combination with estradiol valerate under the brand name Gynodian Depot among others, is a weak androgen, estrogen, and neurosteroid medication which is used as a component of menopausal hormone therapy to treat menopausal symptoms in women. It is available only as an injectable preparation in combination with estradiol valerate. The medication is given by injection into muscle typically once ever 4 weeks.
|Trade names||With estradiol valerate: Gynodian Depot, others|
|Synonyms||DHEA enanthate; Prasterone heptanoate; DHEA heptanoate; DHEA-E; EDHEA; SH-90300-D; SH-70833-D (with EV); Androst-5-en-3β-ol-17-one 3β-heptanoate|
|Drug class||Androgen; Anabolic steroid; Androgen ester; Estrogen; Neurosteroid|
|Metabolites||• Prasterone (DHEA)|
|Elimination half-life||IM: 9 days|
IV: 44 minutes
|Duration of action||18 days|
|Chemical and physical data|
|Molar mass||400.603 g·mol−1|
|3D model (JSmol)|
Prasterone enanthate is a synthetic androgen, estrogen, and neurosteroid. It is a steroid ester and a long-lasting prodrug of prasterone (dehydroepiandrosterone; DHEA) in the body. Prasterone is a naturally occurring prohormone of androgens and estrogens and hence is an agonist of the androgen and estrogen receptors, the respective biological targets of androgens like testosterone and estrogens like estradiol. Prasterone also has a variety of activities of its own, including neurosteroid and other activities. An injection of prasterone enanthate has a duration of action in terms of elevated prasterone levels of about 18 days.
The combination of estradiol valerate and prasterone enanthate was developed as early as 1966 and was introduced for medical use in 1975. The formulation is marketed widely throughout Europe, and is also available in several Latin American countries and in Egypt. It is not available in any predominantly English-speaking countries.
The combination of estradiol valerate and prasterone enanthate is used in menopausal hormone therapy to treat menopausal symptoms in peri- and postmenopausal women. Estradiol valerate serves as an estrogen in the preparation, while prasterone enanthate is intended to serve as a weak androgen. It is thought that the inclusion of prasterone enanthate in the formulation may provide additional psychotropic benefits.
|Route||Medication||Form(s)||Major brand name(s)||Dosage|
|Oral||Testosterone undecanoatea||Capsule||Andriol, Jatenzo||40–80 mg 1x/1–2 days|
|Methyltestosteroneb||Tablet||Metandren; Estratest||0.5–10 mg/day|
|Prasterone (DHEA)c||Tablet||N/A||25–100 mg/day|
|Testosterone||Cream; Gel||AndroGel||5–10 mg/day|
|Vaginal||Testosteroned||Cream; Gel||N/A||? mg 1x/1–3 days|
|Testosteroned||Suppository||N/A||1 mg 1x/2 days|
|Prasterone (DHEA)||Insert||Intrarosa||6.5 mg/day|
|Intramuscular||Testosterone enanthateb||Oil||Delatestryl; Primodian Depot||25–100 mg 1x/4–6 weeks|
|Testosterone cypionateb||Oil||Depo-Testost.; Depo-Testadiol||25–100 mg 1x/4–6 weeks|
|Testosterone isobutyratea,b||Water||Femandren M, Folivirin||25–50 mg 1x/4–6 weeks|
|Testosterone EBHb,e||Oil||Climacteron||150 mg 1x/4–8 weeks|
|Nandrolone decanoate||Oil||Deca-Durabolin||25–50 mg 1x/6–12 weeks|
|Prasterone enanthatea,b||Oil||Gynodian Depot||200 mg 1x/4–6 weeks|
|Subcutaneous||Testosterone||Implant||Testopel||50–100 mg 1x/3–6 months|
|Footnotes: a = Not available or no longer available in the United States. b = Alone and/or in combination with an estrogen. c = Over-the-counter. d = Compounded only. e = Discontinued. Sources: See template.|
Prasterone enanthate, in combination with estradiol valerate at the dosages used clinically, has no masculinizing side effects. This is in contrast to combinations of estrogens with other androgens, such as testosterone esters.
Prasterone enanthate is a prodrug of prasterone in the body. It is completely hydrolyzed into prasterone and heptanoic acid (enanthic acid) following absorption from the tissue depot after intramuscular injection.
Levels of DHEA peak at about 9 ng/mL within 1 to 4 days of an injection of prasterone enanthate. Subsequently, DHEA levels return to baseline by about 18 days following the injection. Prasterone enanthate has an elimination half-life of about 9 days. The plasma half-life of DHEA/prasterone enanthate following an intravenous injection is about 44 minutes. The half-lives of DHEA metabolites range up to 3.6 days.
Within 30 days, 91% of a dose of prasterone enanthate is eliminated. Approximatley 94% is excreted in urine and 6% in feces. Prasterone enanthate is eliminated mainly in the form of metabolites and conjugates.
Prasterone enanthate, also known as 5-dehydroepiandrosterone 3β-enanthate or as androst-5-en-3β-ol-17-one 3β-heptanoate, is a synthetic androstane steroid and the C3β heptanoate (enanthate) ester of prasterone (5-dehydroepiandrosterone).
Prasterone enanthate was patented by Schering in 1968 and 1971. The combination of estradiol valerate and prasterone enanthate was developed and marketed by Schering, was first tested clinically as early as 1966, was first described in the scientific literature in 1972, and was first introduced for medical use in April 1975.
Society and cultureEdit
The major brand name of the combination of estradiol valerate and prasterone enanthate is Gynodian Depot. Other brand names of this formulation include Binodian Depot, Cidodian Depot, Klimax, and Supligol NF.
The combination of estradiol valerate and prasterone enanthate is marketed widely throughout Europe, and is also available in several Latin American countries and in Egypt. In Europe, it is available in Austria, the Czech Republic, France, Germany, Italy, Poland, Russia, Spain, and Switzerland. In Latin America, it is available in Argentina, Chile, Mexico, and Venezuela. The medication is not available in any predominantly English-speaking countries, including the United States, Canada, the United Kingdom, Ireland, Australia, New Zealand, or South Africa.
- Düsterberg B, Wendt H (1983). "Plasma levels of dehydroepiandrosterone and 17 beta-estradiol after intramuscular administration of Gynodian-Depot in 3 women". Horm. Res. 17 (2): 84–9. PMID 6220949.
- Kuhl, Herbert; Taubert, Hans-Dieter (1987). Das Klimakterium – Pathophysiologie, Klinik, Therapie [The Climacteric – Pathophysiology, Clinic, Therapy] (in German). Stuttgart, Germany: Thieme Verlag. p. 122. ISBN 978-3137008019.
- J. Horsky; J. Presl (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 146–. ISBN 978-94-009-8195-9.
- D. Platt (6 December 2012). Geriatrics 3: Gynecology · Orthopaedics · Anesthesiology · Surgery · Otorhinolaryngology · Ophthalmology · Dermatology. Springer Science & Business Media. pp. 6–. ISBN 978-3-642-68976-5.
- S. Campbell (6 December 2012). The Management of the Menopause & Post-Menopausal Years: The Proceedings of the International Symposium held in London 24–26 November 1975 Arranged by the Institute of Obstetrics and Gynaecology, The University of London. Springer Science & Business Media. pp. 395–. ISBN 978-94-011-6165-7.
- Carrie Bagatell; William J. Bremner (27 May 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 277–. ISBN 978-1-59259-388-0.
- Frigo P, Eppel W, Asseryanis E, Sator M, Golaszewski T, Gruber D, Lang C, Huber J (1995). "The effects of hormone substitution in depot form on the uterus in a group of 50 perimenopausal women--a vaginosonographic study". Maturitas. 21 (3): 221–5. doi:10.1016/0378-5122(94)00893-c. PMID 7616871.
- Muller (19 June 1998). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. pp. 566–. ISBN 978-3-7692-2114-5.
- A. Kleemann; J. Engel; B. Kutscher; D. Reichert (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 1172–1174, 2441–2442. ISBN 978-3-13-179525-0.
- Melanie Johns Cupp; Timothy S. Tracy (10 December 2002). Dietary Supplements: Toxicology and Clinical Pharmacology. Springer Science & Business Media. pp. 123–147. ISBN 978-1-59259-303-3.
- Prough RA, Clark BJ, Klinge CM (April 2016). "Novel mechanisms for DHEA action". J. Mol. Endocrinol. 56 (3): R139–55. doi:10.1530/JME-16-0013. PMID 26908835.
- Picha E, Weghaupt K (March 1972). "Erfahrungen mit einer neuen Hormonkombination bei klimakterischen Beschwerden" [Experience with a new hormone combination for menopausal disorders]. Med Klin (in German). 67 (11): 382–6. ISSN 0025-8458. PMID 4259772.
A new hormone combination for menopausal complaints. Since the treatment of menopausal complaints with estrogens as well as with the combination of estrogens and androgens causes undesired side effects such as bleeding, mammary changes and masculinisation, dehydroepiandrosteron (DHEA), a precursor of testosteron, has been synthesised, which has only a low conversion rate to free testosteron and no masculinising effect. The substance has been tested in combination with estrogen (200 mg DHEA-enanthate and 4 mg estradiolvalerianate per 1 ml) in 266 women with menopausal complaints. The duration of treatment has been up to 6 years with an injection interval of 3 to 8 weeks. The therapeutic results were as good as with estrogen-androgen-combinations, but there was no masculinising effect. Changes of voice, hair and libido caused by pretreatment partly disappeared. Side effects [such] as acne, mastodynia, and sensation of repletion were of transitory nature. This preparation seems to be a true alternative to the traditional estrogen-androgen-combinations.
- Florian Sauer (February 2008). Erfolgsfaktoren für das marktorientierte Management patentgeschützter Arzneimittel: eine Analyse der Produktwahrnehmung niedergelassener Vertragsärzte unter der Berücksichtigung unsicherer Therapieergebnisse. BoD – Books on Demand. pp. 37, 346. ISBN 978-3-936863-12-3.
- William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 1208–. ISBN 978-0-8155-1856-3.
- Lauritzen, C (1980). "Erfahrungen in der Behandlung klimakterischer Beschwerden mit Depot-Injektionen von Östradiolvalerianat-Dehydroepiandrosteronönanthat" [Experience of treatment of climacteric symptoms with depot injections of estradiol valerianate-dehydroandrosterone enantate]. Die Therapiewoche. 30 (10): 1736–1742. ISSN 0040-5973.
A trial of estradiol valerianate-dehydroandrosterone oenantate (Gynodian-Depot) was conducted in 68 post-menopausal women. The treatment exerted a very favorable influence on the typical subjective disorders of the climacteric and on the atrophic alterations of the target organs. Owing to its estrogenic and dehydroepiandrosterone components, the compound also exerts a favorable psychotropic effect. It was tolerated well and caused no side effects of any significance.
- Jurczok F (March 1976). "Behandlung des klimakterischen Symptomenkomplexes mit einem neuen Hormon-Kombinationspräparat" [Treatment of the climacteric symptom complex with a new combined hormone preparation]. Fortschr. Med. (in German). 94 (9): 524–7. ISSN 0015-8178. PMID 134967.
- Dinulović D, Radonjić G (1987). "Gynodian-depot u lecenju kastracione postmenopauze" [Gynodian-depot in the treatment of castration-induced postmenopause]. Jugosl Ginekol Perinatol (in Croatian). 27 (1–2): 37–40. ISSN 0352-5562. PMID 2960859.
- Rauramo L, Punnonen R, Kaihola LH, Grönroos M (January 1980). "Serum oestrone, oestradiol and oestriol concentrations in castrated women during intramuscular oestradiol valerate and oestradiolbenzoate-oestradiolphenylpropionate therapy". Maturitas. 2 (1): 53–8. doi:10.1016/0378-5122(80)90060-2. PMID 7402086.
- Nyholm H, Plesner R (1979). "Serum testosterone, FSH/LH and urinary excretion of estrogens and corticoids during treatment with an injectable, longacting estrogen-DHEA preparation". Acta Obstet Gynecol Scand. 58 (4): 385–8. doi:10.3109/00016347909154601. PMID 160742.
- J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–. ISBN 978-1-4757-2085-3.
- John W. Blunt; Murray H. G. Munro (19 September 2007). Dictionary of Marine Natural Products with CD-ROM. CRC Press. pp. 1075–. ISBN 978-0-8493-8217-8.
- Manfred Kaufmann; Serban-Dan Costa; Anton Scharl (27 November 2013). Die Gynäkologie. Springer-Verlag. pp. 917–. ISBN 978-3-662-11496-4.